Just as precision in vector design leads to groundbreaking scientific advancements, meticulous data analysis, iterative refinement and strategic resource alignment can help drive business success.

Puma Biotechnology announced the design of the Phase 2 alisertib trial for treatment of HER2-, HR+ metastatic breast cancer (PUMA-ALI-1201).